TABLE IV.

Results from CheckMate 142⁷⁵,^a

Study cohort	Treatment	Pts (n)	RR (%)	mPFS (months)	mOS (months)	12-Month OS (%)
Treatment-naïve	Nivolumab 3 mg/kg every 2 weeks, plus ipilimumab 1 mg/kg every 6 weeks	45	60	Not reached	Not reached	83
Pretreated	Nivolumab 3 mg/kg every 2 weeks	74	31	14	Not reached	73
Pretreated	Nivolumab 3 mg/kg every 3 weeks for 4 cycles, then every 2 weeks thereafter, plus ipilimumab 1 mg/kg every 3 weeks for 4 cycles	119	55	Not reached	Not reached	85

^aPhase II trial in patients with deficient mismatch repair or high microsatellite instability metastatic colorectal cancer. Nivolumab is a PD-1 inhibitor. Ipilimumab is a CTLA-4 inhibitor. Response rate and mPFS are determined per the Response Evaluation Criteria in Solid Tumors, version 1.1.

Pts = patients; RR = response rate; mPFS = median progression free survival; mOS = median overall survival; OS = overall survival.